Antihypertensives in dermatology Part I - Uses of antihypertensives in dermatology

Dapsone and its uses in dermatology

Dapsone first came into medicine as an antibacterial agent but was found to be less effective than other sulfonamides. Likewise its activity against tuberculosis was disappointing. Nevertheless, it has been the main stay in the treatment of leprosy. It also has some action against malaria and other parasites. Nowadays, after leprosy, dapsone has proved as a valuable drug in the treatment of a w...

Biosimilars in Dermatology: Current Situation (Part I).

The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more biosimilars can be expected to follow in the coming months and years. Logically, this new situation will have economic repercussions and alter prescribing patterns among dermatologists. In this article, we review regulatory issues related to the ...

Antihypertensives in octogenarians.

The Hypertension in the Very Elderly Trial (HYVET) is one of the most important trials in the history of antihypertensive treatment. It showed that the use of antihypertensive drugs to reduce high blood pressure in patients aged 80 years or more was associated with a significant and marked reduction in the incidence of stroke and heart failure. It also found that treatment reduces all cause mor...

Controversies in Dermatology: Part II.

Peroxisomes in dermatology. Part II.

BACKGROUND Peroxisomes are small cellular organelles that were almost ignored for years because they were believed to play only a minor role in cellular functions. However, it is now known that peroxisomes play an important role in regulating cellular proliferation and differentiation as well as in the modulation of inflammatory mediators. In addition, peroxisomes have broad effects on the meta...